PE-BBI

General Information


DCTPep ID  DCTPep00839

Peptide Name   PE-BBI

Sequence  GALKGCWTKSIPPKPCK

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  skin secretion of Pelophylax esculentus (PE) named PE-BBI

Type  Native peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
HCT 116 Colon carcinoma IC50=35.4 μM MTT assay 24h 1
DLD-1 Colon adenocarcinoma IC50=50.1 μM MTT assay 24h 1
DKs-8 Colon adenocarcinoma IC50=9.8 μM MTT assay 24h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HKE3: IC50=50.2 μM

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep00839

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C82H136N22O20S2

Absent amino acids  DEFHMNQRVY

Theoretical pI  9.70

Acidic residues  0

Basic residues  4

Polar residues  6

Molecular weight (Average)  1814.24

Molecular weight (Monoisotopic)  1812.97

Common amino acids  K

Net charge  4

Instability index (II)  0.28

Aliphatic index  51.76

Grand average of hydropathicity (GRAVY)  -0.500

Half Life 
  30 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 5625
  Abs 0.1% (=1 g/l) 3.100, assuming all pairs of Cys residues form cystines
  Ext. coefficient 5500
  Abs 0.1% (=1 g/l) 3.032, assuming all Cys residues are reduced

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30267012

Title  Identification and pharmaceutical evaluation of novel frog skin-derived serine proteinase inhibitor peptide-PE-BBI (Pelophylax esculentus Bowman-Birk inhibitor) for the potential treatment of cancer

Doi 10.1038/s41598-018-32947-5

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DCTPep is developed by Dr.Zheng's team.